You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 55 No. 9, September 1998 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (71)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Alzheimer Disease
 •Neuropathology
 •Alert me on articles by topic

Differential Level of Platelet Amyloid {beta} Precursor Protein Isoforms

An Early Marker for Alzheimer Disease

Monica Di Luca, PhD; Lucia Pastorino, PhD; Angelo Bianchetti, MD; Jorge Perez, MD, PhD; Luigi A. Vignolo, MD; Gian Luigi Lenzi, MD; Marco Trabucchi, MD; Flaminio Cattabeni, PhD; Alessandro Padovani, MD, PhD

Arch Neurol. 1998;55:1195-1200.

Objective  To determine whether a differential level of platelet amyloid {beta} precursor protein (APP) isoforms is specifically related to Alzheimer disease (AD) and whether it shows a correlation with the progression of clinical symptoms.

Design  After subjects were grouped according to diagnosis and severity of dementia, APP isoform levels in platelets were compared.

Setting  University medical centers.

Patients  Thirty-two patients who fulfilled diagnostic criteria for probable AD, 25 age-matched control subjects, and 16 patients with non-AD dementia.

Main Outcome Measure  The levels of APP isoforms were evaluated by means of Western blot analysis and immunostaining of whole platelets. Messenger RNAs for APP transcripts were also evaluated by means of reverse transcriptase polymerase chain reaction.

Results  The ratio between the intensity of the 130-kd and 106- to 110-kd APP isoforms was significantly lower in the AD group (0.31±0.15, mean±SD) compared with both controls (0.84±0.2) and non-AD subjects (0.97±0.4). The ratio of platelet APP isoforms in patients with AD grouped by Clinical Diagnostic Rating score significantly correlated with the severity of the disease (Pearson correlation coefficient, followed by Bonferroni correction, P =.01). Reverse transcriptase polymerase chain reaction experiments showed that APP transcripts in all experimental groups were equally expressed.

Conclusions  The pattern of platelet APP isoforms is specifically altered in patients with AD. In addition, the alteration of platelet APP isoforms shows a positive correlation with the progression of clinical symptoms, supporting the possibility to consider this peripheral parameter as a marker of progression of the disease. These alterations are not related to abnormalities of APP isoforms messenger RNAs in platelets.


From the Institute of Pharmacological Sciences, University of Milan, Milan, Italy (Drs Di Luca, Pastorino, Perez, and Cattabeni); Alzheimer Disease Unit, Sacro Cuore Fatebenefratelli Hospital, IRCCS, San Giovanni di Dio, Brescia, Italy (Drs Bianchetti); Institute of Neurology, University of Brescia (Drs Vignolo and Padovani); Department of Neurological Sciences, University of Rome, Rome, Italy (Dr Lenzi); and Geriatric Research Group, Brescia (Dr Trabucchi).


RELATED ARTICLE

Alzheimer Disease–Related Abnormalities of Amyloid {beta} Precursor Protein Isoforms in the Platelet: The Brain's Delegate in the Periphery?
Ashley I. Bush and Rudolph E. Tanzi
Arch Neurol. 1998;55(9):1179-1180.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Concept of Disease in Geriatric Psychiatry
Krishnan
AJGP 2007;15:1-11.
ABSTRACT | FULL TEXT  

Multiple-Level Studies Are Needed to Assess the True Value of Diagnostic Tests for Dementia
Van Gool
Arch Neurol 2006;63:142-143.
FULL TEXT  

Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer disease
Colciaghi et al.
Neurology 2004;62:498-501.
ABSTRACT | FULL TEXT  

Correlation of statin-increased platelet APP ratios and reduced blood lipids in AD patients
Baskin et al.
Neurology 2003;60:2006-2007.
ABSTRACT | FULL TEXT  

Lymphocyte Oxidative DNA Damage and Plasma Antioxidants in Alzheimer Disease
Mecocci et al.
Arch Neurol 2002;59:794-798.
ABSTRACT | FULL TEXT  

Abnormalities in the Pattern of Platelet Amyloid Precursor Protein Forms in Patients With Mild Cognitive Impairment and Alzheimer Disease
Padovani et al.
Arch Neurol 2002;59:71-75.
ABSTRACT | FULL TEXT  

Amyloid Precursor Protein in Platelets of Patients With Alzheimer Disease: Effect of Acetylcholinesterase Inhibitor Treatment
Borroni et al.
Arch Neurol 2001;58:442-446.
ABSTRACT | FULL TEXT  

Platelet APP isoform ratios correlate with declining cognition in AD
Baskin et al.
Neurology 2000;54:1907-1909.
ABSTRACT | FULL TEXT  

Sporadic Inclusion Body Myositis Correlates with Increased Expression and Cross-linking by Transglutaminases 1 and 2
Choi et al.
J. Biol. Chem. 2000;275:8703-8710.
ABSTRACT | FULL TEXT  

Abnormalities of Amyloid {beta} Precursor Protein Expression in Platelets of Patients With Alzheimer Disease: Do We Understand Them Well Enough?
Blasko et al.
Arch Neurol 1999;56:889-891.
FULL TEXT  

Alzheimer Disease-Related Abnormalities of Amyloid {beta} Precursor Protein Isoforms in the Platelet: The Brain's Delegate in the Periphery?
Bush and Tanzi
Arch Neurol 1998;55:1179-1180.
FULL TEXT  

Misregulation of gene expression in primary fibroblasts lacking poly(ADP-ribose) polymerase
Simbulan-Rosenthal et al.
Proc. Natl. Acad. Sci. USA 2000;97:11274-11279.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1998 American Medical Association. All Rights Reserved.